SCHEMBL17624126

SCHEMBL17624126

COCCOc1ccc2c(n1)CN(C)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TIPARP Q7Z3E1 7/20 0.50
▸ FFAR1 O14842 1/20 0.43
▸ KDM1A O60341 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PDCD1 Q15116 4/20 0.33
▸ CD274 Q9NZQ7 4/20 0.33
▸ TSHR P16473 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ AKT2 P31751 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ PIK3CG P48736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19505169 0.84 TIPARP (0.47) TIPARPFFAR1MEN1MAPTKMT2A
SCHEMBL19498184 0.84 TIPARP (0.50) TIPARPFFAR1MEN1MAPTKMT2A
SCHEMBL19505171 0.82 TIPARP (0.47) TIPARPFFAR1PDCD1CD274TSHR
SCHEMBL17624120 0.82 HTT (0.38) TIPARPMAPTPDCD1CD274GABRG2
SCHEMBL17624393 0.80 HTR1D (0.39) TIPARPMEN1KMT2ADRD2
SCHEMBL17624122 0.77 DRD3 (0.38) GABRG2GABRB3GABRA5KCNH2DRD2
SCHEMBL17623871 0.75 HSP90AA1 (0.45) TIPARPKDM1AMEN1KMT2A
SCHEMBL12853685 0.71 TIPARP (0.51) TIPARPMAPT
SCHEMBL1039931 0.71 HRH3 (0.55) —
SCHEMBL18034936 0.68 CYP2C19 (0.47) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-26 — — US disclosed
WO-2016044604-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, ADRM1, PRMT1 TIPARP 334/4885FFAR1 2669/4885KDM1A 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback